We are happy and proud to finally announce that CarboHyde won a 2024-1.2.7-EUROSTARS-2025-00007 grant and shall receive ~190,000k Eur to develop a novel cyclodextrin-based Alzheimer asset.
The development will be done in a consortium involving Renatus and Ajou University.
The novel mechanism of action focuses on cholesterol modulation in this neurodegenerative disease and will aim to complete most IND-enabling preclinical studies so that regulatory filings and clinical studies can begin shortly.
